Amgen’s lung cancer drug tarlatamab has received approval from China’s National Medical Products Administration, according to its development and commercialization partner BeOne Medicines, which announced the news on Friday via WeChat.
Tarlatamab is a targeted immunotherapy designed for adults with extensive-stage, hard-to-treat small cell lung cancer whose disease has progressed despite chemotherapy.
Read Also – U.S. fertility rate falls to record low in 2025 as number of births declines
The U.S. drugmaker markets tarlatamab in its domestic market under the brand name Imdelltra. The therapy is part of Amgen’s pipeline of bispecific antibodies, which are designed to bind simultaneously to cancer cells and immune cells, effectively bringing them together so the body’s immune system can more efficiently destroy the cancer.
Amgen and Hong Kong-listed BeOne Medicines did not respond to requests for comment regarding the launch timeline or pricing for the Chinese market.
Some Wall Street analysts have estimated that tarlatamab could generate more than $2 billion in annual sales opportunity for Amgen.
